Abstract Decorporation therapy with salts of diethylenetriamine-pentaacetic acid binds actinides, thereby limiting uptake to organs and enhancing the rate at which actinides are excreted in urine. International Commission on Radiological Protection reference biokinetic models cannot be used to fit this enhanced exertion simultaneously with the baseline actinide excretion rate that is observed prior to the start of therapy and/or after the effects of therapy have ceased. In this study, the Coordinated Network on Radiation Dosimetry approach, which was initially developed for modeling decorporation of plutonium, was applied to model decorporation of americium using data from a former radiation worker who agreed to donate his body to the US Transuranium and Uranium Registries for research. This individual was exposed to airborne 241Am, resulting in a total-body activity of 66.6 kBq. He was treated with calcium-diethylenetriamine-pentaacetic acid for 7 y. The time and duration of intakes are unknown as no incident reports are available. Modeling of different assumptions showed that an acute intake of 5‐μm activity median aerodynamic diameter type M aerosols provides the most reasonable description of the available pretherapeutic data; however, the observed 241Am activity in the lungs at the time of death was higher than the one predicted for type M material. The Coordinated Network on Radiation Dosimetry approach for decorporation modeling was used to model the in vivo chelation process directly. It was found that the Coordinated Network on Radiation Dosimetry approach, which only considered chelation in blood and extracellular fluids, underestimated the urinary excretion of 241Am during diethylenetriamine-pentaacetic acid treatment; therefore, the approach was extended to include chelation in the liver. Both urinary excretion and whole-body retention could be described when it was assumed that 25% of chelation occurred in the liver, 75% occurred in the blood and ST0 compartment, and the chelation rate constant was 1 × 10−10 pmol−1 d−1. It was observed that enhancement of urinary excretion of 241Am after injection of diethylenetriamine-pentaacetic acid exponentially decreased to the baseline level with an average half-time of 2.2 ± 0.7 d.
[1]
M. Avtandilashvili,et al.
Evaluating Plutonium Intake and Radiation Dose Following Extensive Chelation Treatment.
,
2019,
Health physics.
[2]
B. Miller,et al.
Mapping 241Am Spatial Distribution Within Anatomical Bone Structures Using Digital Autoradiography.
,
2018,
Health physics.
[3]
R. Brey,et al.
Development of the Plutonium-DTPA Biokinetic Model
,
2015,
Health physics.
[4]
B. Breustedt,et al.
Biokinetic modelling of DTPA decorporation therapy: the CONRAD approach.
,
2009,
Radiation protection dosimetry.
[5]
P. Fritsch,et al.
Modelling of bioassay data from a Pu wound treated by repeated DTPA perfusions: biokinetics and dosimetric approaches.
,
2007,
Radiation protection dosimetry.
[6]
E. H. Carbaugh,et al.
Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for Pu.
,
2007,
Radiation protection dosimetry.
[7]
M. Bailey,et al.
IMBA Professional Plus: a flexible approach to internal dosimetry.
,
2006,
Radiation protection dosimetry.
[8]
R. Leggett,et al.
Mayak Worker Study: An Improved Biokinetic Model for Reconstructing Doses from Internally Deposited Plutonium
,
2005,
Radiation research.
[9]
M. Bailey,et al.
The retention of 14C-DTPA in human volunteers after inhalation or intravenous injection.
,
1983,
Health physics.
[10]
N. Wald,et al.
Long-term removal of 241Am using Ca-DTPA.
,
1980,
Health physics.
[11]
Smith Ja,et al.
A mathematical model for estimation of plutonium in the human body from urine data influenced by DTPA therapy.
,
1978
.
[12]
A. Brodsky,et al.
Removal of zinc from humans by DTPA chelation therapy.
,
1973,
Health physics.
[13]
J. Horm,et al.
Urinary excretion of 241Am under DTPA therapy.
,
1971,
Health physics.
[14]
I. Horm.
Techniques for separating americium from urine after DTPA therapy.
,
1971,
Health physics.